Blog
About

21
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          BCR-ABL, a constitutively activated tyrosine kinase, is the product of the Philadelphia chromosome. This enzyme is present in virtually all cases of chronic myeloid leukemia (CML) throughout the course of the disease, and in 20 percent of cases of acute lymphoblastic leukemia (ALL). On the basis of the substantial activity of the inhibitor in patients in the chronic phase, we evaluated STI571 (formerly known as CGP 57148B), a specific inhibitor of the BCR-ABL tyrosine kinase, in patients who had CML in blast crisis and in patients with ALL who had the Ph chromosome.

          Related collections

          Author and article information

          Journal
          N. Engl. J. Med.
          The New England journal of medicine
          New England Journal of Medicine (NEJM/MMS)
          0028-4793
          0028-4793
          Apr 05 2001
          : 344
          : 14
          Affiliations
          [1 ] Division of Hematology and Medical Oncology, Oregon Health Sciences University, Portland 97201, USA. drukerb@ohsu.edu
          Article
          MJBA-441402
          10.1056/NEJM200104053441402
          11287973

          Comments

          Comment on this article